Rating Change
Chardan Capital analysts reiterated a Buy rating on Metagenomi, Inc. Common Stock (NASDAQ:MGX) on July 07, 2026.
Rating Change Chardan Capital analysts reiterated a Buy rating on Metagenomi, Inc. Common Stock (NASDAQ:MGX) on July 07, 2026. Market Context Metagenomi, Inc.

Chardan Capital analysts reiterated a Buy rating on Metagenomi, Inc. Common Stock (NASDAQ:MGX) on July 07, 2026.
Metagenomi, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $1.32 with a market capitalization of $65.7M.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Metagenomi, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 07, 2026 | Chardan Capital | Buy | N/A |
| May 12, 2026 | Wells Fargo | Overweight | N/A |
| Aug 19, 2025 | HC Wainwright & Co. | Buy | N/A |
| Aug 15, 2025 | Chardan Capital | Buy | N/A |
| Aug 14, 2025 | Wells Fargo | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View MGX Stock Page
A Buy rating from Chardan Capital reflects the analyst's outlook on Metagenomi, Inc. Common Stock (NASDAQ:MGX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MGX forecast page.
Current market data
NASDAQ · MGX
$1.16
Unchanged: $0.00 · 0.00%
Live quote updated
Keep reading